Albert Dobi

2.2k total citations
61 papers, 1.2k citations indexed

About

Albert Dobi is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Albert Dobi has authored 61 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 27 papers in Molecular Biology and 17 papers in Cancer Research. Recurrent topics in Albert Dobi's work include Prostate Cancer Treatment and Research (43 papers), Prostate Cancer Diagnosis and Treatment (18 papers) and Cancer, Lipids, and Metabolism (10 papers). Albert Dobi is often cited by papers focused on Prostate Cancer Treatment and Research (43 papers), Prostate Cancer Diagnosis and Treatment (18 papers) and Cancer, Lipids, and Metabolism (10 papers). Albert Dobi collaborates with scholars based in United States, Canada and China. Albert Dobi's co-authors include Shiv Srivastava, György Petrovics, Isabell A. Sesterhenn, David G. McLeod, Lakshmi Ravindranath, Yongmei Chen, Bungo Furusato, Jennifer Cullen, Syed Shaheduzzaman and D. G. R. McLeod and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Albert Dobi

60 papers receiving 1.1k citations

Peers

Albert Dobi
Anjana Menon United States
Cai Bowen United States
Xiaoqun Yang China
Beth E. Helgeson United States
Morag Seywright United Kingdom
Silvia Rita Vitale Italy
Fraser Symmans United States
Maurizia Mello‐Grand Italy
Hung‐Wei Pan Taiwan
Zaida García‐Casado Spain
Anjana Menon United States
Albert Dobi
Citations per year, relative to Albert Dobi Albert Dobi (= 1×) peers Anjana Menon

Countries citing papers authored by Albert Dobi

Since Specialization
Citations

This map shows the geographic impact of Albert Dobi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Dobi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Dobi more than expected).

Fields of papers citing papers by Albert Dobi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Dobi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Dobi. The network helps show where Albert Dobi may publish in the future.

Co-authorship network of co-authors of Albert Dobi

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Dobi. A scholar is included among the top collaborators of Albert Dobi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Dobi. Albert Dobi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenberg, Matt T., Albert Dobi, Amina Ali, et al.. (2024). Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men. Cancers. 16(4). 712–712. 2 indexed citations
2.
Kohaar, Indu, et al.. (2024). Germline Mutations and Ancestry in Prostate Cancer. Current Oncology Reports. 26(2). 175–180. 1 indexed citations
3.
Ghandadi, Morteza, Albert Dobi, & Sanjay V. Malhotra. (2024). A role for RIO kinases in the crosshair of cancer research and therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(3). 189100–189100. 2 indexed citations
4.
Nousome, Darryl, Huai‐Ching Kuo, Lakshmi Ravindranath, et al.. (2023). Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men. Biomedicines. 11(5). 1404–1404. 1 indexed citations
5.
6.
Dobi, Albert, et al.. (2022). Emerging Developments in ETS-Positive Prostate Cancer Therapy. Molecular Cancer Therapeutics. 22(2). 168–178. 4 indexed citations
7.
8.
Mohamed, Ahmed A., Charles P. Xavier, Gauthaman Sukumar, et al.. (2018). Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. Cancer Research. 78(13). 3659–3671. 44 indexed citations
9.
Xiao, Qingyu, Yidi Sun, Albert Dobi, et al.. (2018). Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer. Scientific Reports. 8(1). 12868–12868. 16 indexed citations
10.
Mohamed, Ahmed A., Shyh‐Han Tan, Charles P. Xavier, et al.. (2017). Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells. Molecular Cancer Research. 15(10). 1308–1317. 33 indexed citations
11.
Griner, Nicholas B., Denise Young, Pankaj Chaudhary, et al.. (2014). ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer. Molecular Cancer Research. 13(2). 368–379. 11 indexed citations
12.
Sesterhenn, Isabell A., Inger L. Rosner, Jennifer Cullen, et al.. (2013). Anterior tumors of the prostate: clinicopathological features and outcomes. Prostate Cancer and Prostatic Diseases. 17(1). 75–80. 36 indexed citations
13.
Furusato, Bungo, Syed Shaheduzzaman, Vasantha Srikantan, et al.. (2011). Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer and Prostatic Diseases. 15(2). 150–156. 56 indexed citations
14.
Sterbis, Joseph R., Chunling Gao, Bungo Furusato, et al.. (2008). Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival. Clinical Cancer Research. 14(3). 758–763. 18 indexed citations
15.
Thangapazham, Rajesh L., Syed Shaheduzzaman, Kee‐Hong Kim, et al.. (2008). Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biology & Therapy. 7(9). 1427–1435. 34 indexed citations
16.
Furusato, Bungo, Chunling Gao, Lakshmi Ravindranath, et al.. (2007). Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer. Modern Pathology. 21(2). 67–75. 115 indexed citations
17.
Furusato, Bungo, Syed Shaheduzzaman, György Petrovics, et al.. (2007). Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer and Prostatic Diseases. 11(2). 194–197. 25 indexed citations
18.
Shaheduzzaman, Syed, Bungo Furusato, Jennifer Cullen, et al.. (2007). Silencing of lactotransferrin expression by methylation in prostate cancer progression. Cancer Biology & Therapy. 6(7). 1088–1095. 46 indexed citations
19.
Dobi, Albert, Syed Shaheduzzaman, Chang-Hao Gao, et al.. (2006). Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase. Prostate Cancer and Prostatic Diseases. 10(1). 30–38. 14 indexed citations
20.
Sun, Chen, Yuguang Shi, Leland Davis, et al.. (2006). Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene. 25(28). 3905–3913. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anjana Menon Breakdown of academic impact, for papers by Cai Bowen Breakdown of academic impact, for papers by Xiaoqun Yang Breakdown of academic impact, for papers by Beth E. Helgeson Breakdown of academic impact, for papers by Morag Seywright Breakdown of academic impact, for papers by Silvia Rita Vitale Breakdown of academic impact, for papers by Fraser Symmans Breakdown of academic impact, for papers by Maurizia Mello‐Grand Breakdown of academic impact, for papers by Hung‐Wei Pan Breakdown of academic impact, for papers by Zaida García‐Casado
Rankless by CCL
2026